ABSTRACT
Erythema multiforme (<1%) (1999): Yosipovitch G+, J Am Acad Dermatol 41, 473 Erythema nodosum (<1%) Exanthems (1-11.9%) (2000): Prost C+, Presse Med (French) 29, 303 (1999): Yosipovitch G+, J Am Acad Dermatol 41, 473 (1997): Litt JZ, Beachwood, OH (personal case) (observation) (1990): Mc Tavish D+, Drugs 40, 238 (7%) (1989): Hass WK+, N Engl J Med 321, 501 (11.9%) (1987): Saltiel E+, Drugs 34, 222 (1-5%) Exfoliative dermatitis (<1%) Facial erythema (1999): Yosipovitch G+, J Am Acad Dermatol 41, 473 Fixed eruption (2001): Garcia CM+, Contact Dermatitis 44, 40 (1999): Yosipovitch G+, J Am Acad Dermatol 41, 473 Hematomas (1984): Stiegler H+, Dtsch Med Wochenschr (German) 109, 1240 (2.7%) Lupus erythematosus (positive ANA) (<1%) (2002): Spiera RF+, Arch Intern Med 162(19), 2240 (4 cases) Petechiae (1984): Stiegler H+, Dtsch Med Wochenschr (German) 109, 1240 (1.7%) Phenytoin toxicity (sic) (1998): Klaasen SL, Ann Pharmacother 32, 1295 Pruritus (1.3%) (1999): Yosipovitch G+, J Am Acad Dermatol 41, 473 (1990): Mc Tavish D+, Drugs 40, 238 (1987): Saltiel E+, Drugs 34, 222 Purpura (2.2%) (2000): Chemnitz JM+, Med Klin (German) 95, 96 (2000): Tsai HM+, Ann Intern Med 132, 794 Rash (sic) (5.1%) (1999): Quinn MJ+, Circulation 100, 1667 (1999): Whetsel TR+, Pharmacotherapy 19, 228 Side effects (sic) (1984): Stiegler H+, Dtsch Med Wochenschr (German) 109, 1240 (8%) Stevens-Johnson syndrome (<1%) Thrombocytopenic purpura (2.2%) (2001): Medina PJ+, Curr Opin Hematol 8(5), 286 (2001): Naseer N+, Heart Dis 3(4), 221 (2001): Yang CW+, Ren Fail 23(6), 851 (2 cases) (2000): Tsai H-M+, Ann Intern Med 132, 794 (1999): Bennett CL+, Ann Intern Med 159, 2524 (1999): Chen DK+, Arch Intern Med 159, 311 (1999): Elangovan L, Arch Int Med 159, 1624
(1999): Mauro M+, Blood 94, 1-646a (1999): Steinhubl SR+, JAMA 281, 806 (1998): Bennett CL+, Ann Intern Med 128, 541 (1998): Bennett CL+, Lancet 352, 1036 (1998): Jamar S+, Acta Cardiol 53, 285 (1998): Mukamal KJ+, Ann Intern Med 129, 837 (1998): Muszkat M+, Pharmacotherapy 18, 1352 (1997): Kupfer Y+, N Engl J Med 337, 1245 (1996): Wysowski DK+, JAMA 276, 952 (1991): Page Y+, Lancet 337, 774 (1990): McTavish D+, Drugs 40, 238 (1-5%) (1990): Takishita S+, N Engl J Med 323, 1487 (1989): Hass WK+, N Engl J Med 321, 501 (4%) (1984): Stiegler H+, Dtsch Med Wochenschr (German) 109, 1240 (1-5%) (1982): de Fraiture WH+, Ned Tijdschr Geneeskd (Dutch) 126, 1051 Toxic erythroderma (sic) (1999): Hsi DH+, N Engl J Med 340, 1212 Urticaria (<1%) (1999): Yosipovitch G+, J Am Acad Dermatol 41, 473 (1990): McTavish D+, Drugs 40, 238 (1989): Hass WK+, N Engl J Med 321, 501 (2%) (1987): Saltiel E+, Drugs 34, 222 (1-5%) Vasculitis (<1%) (2001): Pintor E+, Rev Esp Cardiol 54(1), 114
Other Erythromelalgia
(1999): Yosipovitch G+, J Am Acad Dermatol 41, 473 Headache Serum sickness Tinnitus
Trade names: Betimol; Blocadren (Merck); CoSopt (Merck); Timolide (Merck); Timoptic (ophthalmic) (Merck)
Other common trade names: Apo-Timol; Aquanil; Dispatim; Nu-Timolol; Tenopt; Tiloptic; Timacor; Timoptol
Indications: Hypertension Category: Antihypertensive; Beta-adrenoceptor blocker Half-life: 2-2.7 hours Clinically important, potentially hazardous interactions with: clonidine,
epinephrine, ergot, verapamil CoSopt is timolol and dorzolamide; Timolide is timolol and hydrochlorothiazide.
